Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping cl
Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibito
The Phase 2b INSIGHT study demonstrates that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) is highly effective and safe for treating HIV in patients receiving rifampicin-based tuberculosis therapy, achieving over 94
This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living wi
Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.
Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV r
Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.
A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patient
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.